{"lc": 1, "type": "constructor", "id": ["langchain", "schema", "document", "Document"], "kwargs": {"metadata": {"source": "/home/guanzhideng145/research/ip_portal/patent_kg/patents/721-US20210060002A1(Pending) not sealed.pdf"}, "page_content": "a structure of Formula ( IIb ) , ( IIIb ) , or ( IVb ) :\n\nFormula ( IIb )\n\n. : 1117\n\nFormula ( III )\n\nN.\n\nFormula ( IIIb )\n\nN\n\nOH\n\nor\n\nor\n\nN\n\nNO2\n\nUS 2021/0060002 A1\n\nMar. 4, 2021\n\nwherein Ri, Ra, R3, Ry are independently selected from a hydrogen atom, a C1-C3 alkyl group, a halogen atom or a nitrogen containing group, and with the provision that the analogue is not tetrandrine. C1-C3 alkyl group may be any of a methyl group, an ethyl group, a propyl group, an isopropyl group, or a cyclopropyl group. The halogen atom may be selected from the group consisting of fluorine, chlorine, and bromine.\n\n-continued\n\nNo | IN OH 9 CO} N. ~ Formula | ZA O.\n\n[0055] In an embodiment, the analogue of berbamine preferably has a structure of Formula (ID), (Ill), or (IV):\n\nFormula (11)\n\n[0056] In an embodiment, the analogue of berbamine structure of Formula (IIb), (IIIb), or (IVb):\n\nFormula (IIb)\n\nFormula (IIIb)\n\n] yo 0 fe} Oo A Ss SS NO;\n\n(IV)\n\nhas\n\na\n\nFormula (ID\n\nI \u5168\n\nMar. 4 , 2021\n\nUS 2021/0060002 A1\n\n5\n\n[ 0063 ] The expression \u201c effective amount \" generally\n\ncontinued\n\ndenotes an amount sufficient to produce therapeutically\n\nFormula ( IVb )\n\ndesirable results , wherein the exact nature of the result varies\n\ndepending on the specific condition which is treated . Ber\n\nbamine or its analogue may be contained in a composition ,\n\nin particular a pharmaceutical composition , in an effective\n\namount , i.e. an amount suitable to treat or prevent the RNA\n\nvirus infection particularly flavivirus infection , enterovirus\n\ninfection or lentivirus infection in a subject , in particular a\n\nmammal , which also depends on the frequency and number\n\nH\n\nH\n\nof compositions to be administered . In an embodiment , the\n\nN\n\nsubject is a mammal and berbamine or its analogue may be\n\nadministered to the subject at a dose of about 20 mg / kg to\n\nabout 50 mg / kg , or above . In other embodiment , the subject\n\nis human and berbamine or its analogue may be adminis", "type": "Document"}}